Uveitis Pipeline Insight

DelveInsight’s, “Uveitis – Pipeline Insight, 2023,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Uveitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Uveitis Understanding

Uveitis: Overview

Uveitis is a general term describing a group of inflammatory diseases that produces swelling and destroys eye tissues. These diseases can slightly reduce vision or lead to severe vision loss. Uveitis is swelling of the middle layer of the eye, which is called the uvea. It may occur from both infectious and non-infectious causes. Uveitis is caused by inflammatory responses inside the eye. Inflammation is the body’s natural response to tissue damage, germs, or toxins. It produces swelling, redness, heat, and destroys tissues as certain white blood cells rush to the affected part of the body to contain or eliminate the insult. Uveitis can affect one or both eyes. Symptoms may develop rapidly and can include: Blurred vision, Dark, floating spots in the vision (floaters), Eye pain, Redness of the eye, and Sensitivity to light (photophobia). Diagnosis of uveitis includes a thorough examination and the recording of the patient’s complete medical history. Laboratory tests may be done to rule out an infection or an autoimmune disorder. Uveitis treatments primarily try to eliminate inflammation, alleviate pain, prevent further tissue damage, and restore any loss of vision. Treatments depend on the type of uveitis a patient displays. Some, such as using corticosteroid eye drops and injections around the eye or inside the eye, may exclusively target the eye whereas other treatments, such immunosuppressive agents taken by mouth, may be used when the disease is occurring in both eyes, particularly in the back of both eyes. Other immunosuppressive agents that are commonly used include medications such as methotrexate, mycophenolate, azathioprine, and cyclosporine.

"Uveitis - Pipeline Insight, 2023" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Uveitis pipeline landscape is provided which includes the disease overview and Uveitis treatment guidelines. The assessment part of the report embraces, in depth Uveitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Uveitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Uveitis R&D. The therapies under development are focused on novel approaches to treat/improve Uveitis.

Uveitis Emerging Drugs Chapters

This segment of the Uveitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Uveitis Emerging Drugs

Barcitinib: Eli Lilly and Company

Baricitinib is a selective and reversible Janus kinase 1 (JAK1) and 2 (JAK2) inhibitor. Janus kinases belong to the tyrosine protein kinase family and play an important role in the proinflammatory pathway signalling. Eli Lilly and Company is conducting a Phase III clinical trial to see if the study drug baricitinib given orally is safe and effective in participants with active juvenile idiopathic arthritis (JIA)-associated uveitis or chronic anterior antinuclear antibody-positive uveitis from 2 years to less than 18 years old.

EYS606: Eyevensys

EYS606 is a novel non-viral gene therapy approach being developed for the treatment of chronic non-infectious uveitis (CNIU) is being evaluated in Phase II stage of development. EYS606 combines plasmids encoding a potent fusion protein that neutralizes the activity of TNF-α and the proprietary Eyevensys Electrotransfection System used to introduce the plasmids into the eye. TNF is a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in CNIU. EYS606 has already received orphan designation in Europe and is being investigated in 2 ongoing clinical trials enrolling patients with CNIU.

Further product details are provided in the report……..

Uveitis: Therapeutic Assessment

This segment of the report provides insights about the different Uveitis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Uveitis

There are approx. 15+ key companies which are developing the therapies for Uveitis. The companies which have their Uveitis drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.

Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Uveitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Uveitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Uveitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Uveitis drugs.

Uveitis Report Insights

• Uveitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Uveitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Uveitis drugs?
• How many Uveitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Uveitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Uveitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Uveitis and their status?
• What are the key designations that have been granted to the emerging drugs?